Why is Oxford Nanopore Technologies stock plummeting 20% today? By Investing.com
Oxford Nanopore Technologies shares fell about 20.5% to 96.2p after its scheduled H1 2026 trading update. The company reported first-half revenue of about £116.5m, up 10% (12% at constant currency) but below management expectations. Results were hurt by a 16% China decline from tighter export controls and about a 14% Middle East drop amid geopolitical disruption.
How this was made
The 30-second read
Why it matters
The update disclosed first-half revenue of about £116.5M, growth of 10% reported (12% constant currency), and declines of 16% in China and about 14% in the Middle East, falling short of management expectations and raising doubts about meeting 2026 guidance of 21% to 25% revenue growth.
Market read
A below-expectations revenue print plus geographic revenue declines directly challenge ONT’s full-year growth target, driving a sharp repricing today.
What to watch
Investors may be over-weighting the first-half comparison; the next major datapoint is the full half-year results on 19 August 2026, which could clarify demand and export-control impacts.
Background
Oxford Nanopore released its scheduled H1 2026 trading update, with full half-year results due 19 August 2026.
Ticker impact
Oxford Nanopore shares fell 20.5% after its H1 2026 trading update showed £116.5M revenue, up 10% reported but below expectations.
Bearish near-term as investors reprice the gap versus the 21% to 25% full-year growth guidance.
The article cites a concrete revenue miss versus management expectations plus geographic declines that directly undermine the company’s own full-year guidance.
Market effects
Genomic sequencing peers (Illumina, Pacific Biosciences) face similar China headwinds, but this sell-off is attributed to ONT’s company-specific disclosure.
China and Middle East demand sensitivity is highlighted as a key swing factor for sequencing revenue.
Geopolitical disruption in the Middle East is cited as a driver, but the article frames the move as idiosyncratic to ONT’s update.
Counterpoint
The company’s full-year guidance may still be achievable if the back half normalizes, since the miss is concentrated in China and the Middle East.
Key entities
- companyOxford Nanopore Technologies
Subject of the article, with a H1 2026 trading update that missed expectations and drove a 20% stock drop.
